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The Editorial on the Research Topic
Axonopathy in Neurodegenerative Disease
Within the study of neurodegenerative diseases, axonopathy is increasingly recognized as a
major contributor to the disease manifestation, and in some cases, the key pathogenic driver.
Neurons, with their highly specialized anatomy, must maintain both dendritic arbors and long
axon processes. The loss of the axon effectively disconnects the neuron from its postsynaptic
partners, eliminating its function in neural circuitry. The loss of the axon may be an early symptom
of more extensive degeneration and neuron loss to follow. This has been suggested for diseases
such as amyotrophic lateral sclerosis (ALS), where changes in the distal terminal of motor neurons
presage their eventual death (Fischer et al., 2004). In other cases, such as inherited peripheral
neuropathies, the loss of the axon is the primary feature of the disease, with sensory and motor
deficits manifesting in the distal extremities innervated by the longest neuronal projections
(Cavanagh, 1964).
Many aspects of cell biology converge in maintaining axons and in their degeneration. Their
length requires an elaborate cytoskeleton and transport machinery. Functioning mitochondria
are required to meet local energy demands, again necessitating mitochondrial transport, fusion,
fission, and possibly local translation of mitochondrial components to keep up with organelle and
protein turnover (Misgeld and Schwarz, 2017). Finally, axons are also often intimately associated
with myelinating glial cells, creating a mutually dependent functional unit to maintain axonal
conduction and integrity. This Research Topic of Frontiers in Neuroscience is devoted to these
issues of axon cell biology and the disorders that result from dysfunction in these processes.Many of
the papers included in this Research Topic arose from presentations and discussions held at the 6th
Molecular Mechanisms of Axon Degeneration conference, hosted at The Jackson Laboratory in Bar
Harbor, Maine, in September of 2016. Additional contributions expand the scope of this Research
Topic, particularly into areas related to degeneration of the optic nerve, relevant to glaucoma and
other central neurodegenerations.
The review article by Stassart et al. provides an excellent summary of axon and glial cell biology
and anatomy and how this interdependent relationship changes with disease (Stassart et al.).
Similarly, axons and glial cells develop in concert, and undergo age-related changes that may
predispose or even precipitate neurodegenerative diseases. The review by Salvadores et al. examines
the impact of aging on the anatomy and function of axons (Salvadores et al.). Proper function of the
axon depends on a well-order cytoskeleton. Cytoskeletal abnormalities are common to axon-centric
diseases and toxic neuropathies, with specific chronic conditions such as tauopathies directly
impacting axonal proteins. The review by Kneynsberg et al. examines the mechanisms by which
tau, a microtubule associated protein, contributes to axon degeneration and disease (Kneynsberg
et al.).
Another area of axonopathy research that has received a great deal of attention recently is
chemotherapy-induced peripheral neuropathy (CIPN), a common side-effect of cancer treatment
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that decreases patient quality-of-life and is a major factor limiting
drug dosage (Argyriou et al., 2014). This is a major concern
clinically, but these drugs also provide tools for understanding
axon degeneration and the normal cellular functions that are
required to maintain healthy axons. The review by Fukuda
et al. examines the cellular mechanisms underlying CIPN, which
extend well beyond the impact of these drugs on the microtubule
cytoskeleton (Fukuda et al.).
Axon degeneration is an active process, and this is most
clearly demonstrated in Wallerian degeneration, which involves
the fragmentation and disintegration of an axon distal to the site
of an injury. Genetic studies have identified a spontaneous gain-
of-function mouse mutation, Wallerian Degeneration Slowed
(WLDs), as well as recessive loss-of-function mutations in Sarm1
as mutations that protect against Wallerian degeneration (Mack
et al., 2001; Osterloh et al., 2012). Both WLDs and loss of Sarm1
lead to increased NAD+ levels locally in the axon, which in turn
protects axons from degeneration. The therapeutic potential of
this pathway is demonstrated in the original research article by
Williams et al. which shows that nicotinamide and WLDs act in
concert to prevent retinal ganglion cell axon loss in glaucoma
(Williams et al.).
Like NAD+ levels, local ATP and Ca++ homeostasis in axons
depends on healthy mitochondria, which traffic through, and
are localized in axons. Mutations affecting mitochondrial fusion,
fission, and metabolism lead to an assortment of axonal defects
and are also important in regeneration. The original research
article by Knowlton et al. describes the relationship between
mitochondrial function and the capacity for axon regeneration in
C. elegans (Knowlton et al.). The review by Inman et al. examines
howmetabolic vulnerability specifically in axons andmyelinating
glial cells can contribute to axon loss in glaucoma (Inman and
Harun-Or-Rashid). In contrast to metabolic issues, the original
research article by Rogers et al. suggests that impaired mitophagy
in nerve terminals contributes to the die-back neuropathy of
motor neurons seen in mouse models of ALS (Rogers et al.). The
need to maintain healthy mitochondria far from the cell body is
a recurring theme in many neurodegenerative diseases. This is
one argument favoring local protein synthesis in axons, which
remains a controversial topic in neurobiology. The state of this
question is addressed in the review by Spaulding and Burgess,
including recent in vivo profiling studies of ribosome-associated
mRNAs isolated from axons of the adult mouse visual system that
indicate robust levels of translation, particularly of mitochondrial
components (Spaulding and Burgess).
Axonopathy is often considered in the context of peripheral
motor and sensory neurons, given their length, the presence of
diseases that specifically affect these systems, and their sensitivity
to challenges such as chemotherapy drugs or metabolic disorders
such as diabetes. However, these characteristics are not limited
to the peripheral nervous system. Many of the papers in this
research topic focus on glaucoma, a neuropathy affecting axons
of the optic nerve, one of the few central nervous system
components outside of the brain and spinal cord. Glaucoma
shares commonalities with other central neurodegenerations
such as Alzheimer’s, Parkinson’s, and Huntington’s diseases,
often exhibiting comorbidity with those conditions, as well as
exhibiting similarmechanismswith these and other axonopathies
(Conforti et al., 2007).
Stresses such as hypoxia and oxidative stress arising from
vascular dysfunction contribute to the pathogenesis of glaucoma,
as described in the original research article by Chidlow et al.
As in the degenerating brain, neuroinflammation plays a sizable
role in glaucomatous neurodegeneration. One of this topic’s
original research articles, the loss of the pleiotropic cytokine IL-
6 is shown to protect axons in glaucoma (Echevarria et al.).
The mechanism underlying this protection remains unclear,
but changes in axonal transport appear to be separated from
changes in axon integrity, possibly separating these features in
this model. Another original research article shows that more
conventional inflammatory pathways may also contribute to
glaucoma (Lambert et al.). Treatment with the synthetic steroid
HE3286 reduced axonopathy in a rodent microbead occlusion
model of glaucoma, possibly through its proposed targets
of MAPK/ERK/NFκb signaling. The recurring mechanisms of
axonal transport and cytoskeletal abnormalities are also in play
in the axonopathy of glaucoma, as shown in the original research
articles by Breen et al. and Wilson et al. Finally, the differential
sensitivity of neurons to degeneration is a common yet puzzling
feature of a variety of diseases and neurotoxic conditions. The
review by Vidal-Sanz et al. describes the differential responses
of different retinal ganglion cell populations in animal models
exhibiting either ocular hypertension or optic nerve injury
(Vidal-Sanz et al.). Together, these papers highlight the parallels
of glaucoma and other diseases in which axonopathy is a key
pathophysiological sequela.
Although the mechanisms that lead to axon degeneration
may be shared across a range of diseases, they encompass
a wide range of biological processes including cytoskeleton,
transport, metabolism, translation, and inflammation. Perhaps
this reflects the number of things that normally have to
go correctly to actually preserve an axon, which in turn,
could explain why axonopathy is often the harbinger of
degeneration. Defining these processes is a challenge and predicts
that there will not be a single “magic bullet” to correct all
axonopathies, but the rapidly increasing depth of our knowledge
concerning the functions required to maintain an axon will
ultimately help in understanding how to prevent degeneration
or even to promote regeneration in these diseases in the
future.
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